Biogen, and its Japanese partner Eisai, announced Monday that it plans to begin the process for U.S. approval for its experimental drug for Alzheimer’s.
Biogen and Eisai announced “rolling submission” to the Food and Drug Administration (FDA) for its second Alzheimer’s drug, lecanemab, according to a company press release. The companies expect the submission to be completed in the next several months.
The Daily Caller was founded in 2010 by Tucker Carlson, a 20-year veteran journalist, and Neil Patel, former chief policy advisor to Vice President Cheney, The Daily Caller is one of America’s largest and fastest-growing news publications. Our team of experienced, full-time reporters and editors works around the clock to deliver award-winning original reporting, in-depth investigations, entertainment, thought-provoking commentary and up-to-the-second breaking news. Visit https://dailycaller.com